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Abstract
Background: Diabetes is a major public health issue and there is a need to develop low-cost, novel interventions
to prevent or reduce disease progression. Growing evidence shows that supplementation with carnosine, or its rate-
limiting precursor β-alanine, can ameliorate aspects of the metabolic dysregulation that occurs in diabetes. There is,
however, a need to develop a better understanding of the magnitude of effect and the factors associated with positive
outcomes. The purpose of this systematic review and meta-analysis is to evaluate the effect of carnosine or β-alanine
supplementation on markers of glycaemic control and insulin resistance in humans and animals.
Methods: We will perform a systematic search for randomised and non-randomised controlled trials. Studies will be
retrieved by searching electronic databases, clinical trial registers, author review, and cross-referencing. Primary
outcomes include changes in (i) fasting glucose, (ii) glycated haemoglobin, and (iii) 2-h glucose following a glucose
tolerance test. A set of additional outcomes includes other markers of glycaemic control and insulin resistance. Risk of
bias (RoB) will be assessed using the Cochrane RoB 2.0 tool (human studies) and the Systematic Review Centre for
Laboratory Animal Experimentation (SYRCLE) RoB tool (animal studies). Confidence in the cumulative evidence will be
assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. All
meta-analyses will be conducted within a Bayesian framework, providing a flexible modelling approach to account for
uncertainty in model parameters and underlying structures within the data.
Discussion: By including all available human and animal data, we will provide the most comprehensive overview on
the topic to date. The results will have implications for those working in prediabetes, diabetes, and metabolic health in
general and may lead to the development of new treatment approaches.
Dissemination: Study results will be presented at a professional conference and published in a peer-reviewed journal.
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Background
Diabetes is a major public health problem. Recent esti-
mates show that 4.8 million people in the UK are living
with diabetes, which is expected to rise to 5.3 million by
2025 [1]. Type 2 diabetes accounts for over 90% of these
cases, with the remaining made up of type 1 diabetes,
gestational diabetes, and rarer types of diabetes (e.g. ma-
turity onset diabetes of the young). A hallmark of type 2
diabetes is poor glycaemic control and insulin resistance
[2], which can present earlier in life as impaired fasting
glucose or impaired glucose tolerance (also known as
prediabetes). For individuals aged 45 years, there is a
74% lifetime risk of progression from prediabetes to type
2 diabetes [3]. While lifestyle modifications are central
to risk reduction, they can be challenging to implement,
and long-term adherence limits their effectiveness. It is
therefore important to develop low-cost, novel interven-
tions to improve glycaemic control and help prevent or
delay disease progression.
The multifunctional compound carnosine has emerged
as a candidate for clinical use. Carnosine, a member of
the histidine-containing dipeptide (HCD) family, exists
naturally in high concentrations in mammalian skeletal
muscle and in smaller amounts in other excitable tissues
[4–7]. Contents in skeletal muscle can be increased by
supplementing with carnosine or its rate-limiting pre-
cursor β-alanine [8]. Work from our Research Group
shows that treatment with carnosine decreases highly
toxic lipid peroxidation products in skeletal muscle cells
(unpublished data), leading to an increase in insulin-
stimulated glucose uptake under glucolipotoxic condi-
tions [9]. Further evidence supports the role of carnosine
in non-enzymatic detoxification of reactive aldehydes
[10, 11], an effect that β-alanine supplementation poten-
tiates in vivo [12, 13]. Through these actions, carnosine
may be able to ameliorate aspects of the metabolic dysreg-
ulation that occurs in diabetes and its related conditions.
There is growing evidence from rodent studies that car-
nosine supplementation can prevent or delay the develop-
ment of type 2 diabetes [14, 15]. Initial human trials also
show promise [16, 17], but the factors associated with
positive outcomes are unclear. A recent meta-analysis of
human studies sought to address this knowledge gap, con-
cluding that supplementation with histidine-containing di-
peptides improves waist circumference, fasting glucose,
and glycated haemoglobin (HbA1c) [18]. The review, how-
ever, had several methodological shortcomings (for details,
see [19]), which included combining effects from studies
using multi-ingredient supplements with those supple-
menting carnosine or β-alanine in isolation. This approach
cannot determine whether the beneficial effects are due to
carnosine or β-alanine alone. It is also important to con-
sider relevant outcomes from animal models that can pro-
vide mechanistic insight and help inform future human
research studies. There is a clear need to develop a better
understanding of the magnitude of effect, as well as the
factors associated with supplementation for improving
outcomes. Therefore, the purpose of this systematic
review and meta-analysis is to evaluate the effect of
carnosine or β-alanine supplementation on markers of
glycaemic control and insulin resistance in humans
and animals.
Methods
This protocol follows the Preferred Reporting Items for
Systematic Review and Meta-Analysis Protocols (PRIS
MA-P) [20] and is registered on PROSPERO (registra-
tion number CRD42020191588).
Eligibility criteria
Studies will be selected according to the eligibility cri-
teria outlined in Table 1. There will be no restrictions
on the timing or duration of supplementation and no re-
strictions on the type of setting. English and non-English
language sources will be included with the latter trans-
lated into English using freely available online translators
(e.g. Google or Bing). Any studies that cannot be ad-
equately translated will be excluded from the review and
a list of the titles provided as an appendix.
Information sources
We will search the following electronic databases for
potentially eligible studies: PubMed, Scopus, Web of
Science, Cochrane Central Register of Controlled Trials
(CENTRAL), Cumulative Index to Nursing and Allied
Health Literature (CINAHL), and ProQuest. The elec-
tronic database search will be supplemented by search-
ing for trial protocols listed on trial registers: Clinical
Trials (www.ClinicalTrials.gov), EU Clinical Trials Regis-
ter (www.clinicaltrialsregister.eu), International Standard
Randomised Controlled Trial Number (ISRCTN)
(www.isrctn.com/mrct), and Animal Study Registry
(www.animalstudyregistry.org). To ensure full cover-
age of the literature, we will search the reference lists
and perform citation tracking of included studies and
relevant reviews identified through the search. Review
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authors will also search their own personal files to
identify any potentially relevant material.
Search strategy
Search strategies will be developed using key text words
and Medical Subject Headings (MeSH) related to the
population, intervention, and outcomes (Table 1). A pre-
liminary search strategy for PubMed can be viewed in
the supporting information. The search strategy will be
peer-reviewed by an academic librarian, not otherwise
associated with the project, using the Peer Review of
Electronic Search Strategies (PRESS) approach [23]. This
search strategy will then be adapted for other databases.
Searches will be performed from the earliest record in
each database up to the present day and repeated prior
to submission of the final review to retrieve any articles
published during the interim period.
Initial searches, data extraction, and assessment of risk
of bias steps will be completed independently by two re-
viewers. Full-text screening will be completed independ-
ently by three reviewers. Any disagreements will be
resolved via consensus-based discussion, and remaining
disagreements for searches, data extraction, and risk of
bias will be referred to a third reviewer who will provide
a recommendation.
Study records
Titles and abstracts of articles from the initial searches
will be imported into a systematic review management
platform (Covidence, Veritas Health Innovation Ltd.,
Melbourne; Australia), duplicates removed, and remaining
articles screened for potential eligibility. We will obtain
full texts for all articles that appear to meet the inclusion
criteria or where there is any uncertainty. Each reviewer
will use the reference manager functions to highlight eligi-
bility criteria and add comments on each article, which
allows decisions to be cross-referenced in the event of a
disagreement. Reviewers will not be blinded to the journal
titles or the study authors.
Multiple reports of the same study will be handled by
including the published article that provides the most
relevant outcome data, assuming similar methods and
sample sizes. We will seek additional information from
study authors where necessary to resolve issues regard-
ing eligibility (maximum of three e-mail attempts). A
PRISMA flow diagram that depicts the search process
will be included (see supporting information for a tem-
plate), as well as supporting information that includes a
reference list of all full-text studies excluded, including
reasons for exclusion.
Data will be extracted using a standardised spreadsheet
based on the Cochrane data collection form for inter-
vention reviews [24]. To ensure consistency between re-
viewers, we will conduct calibration exercises before
starting data extraction.
Data items
We will extract data for (i) study characteristics (location,
setting, study design, size, duration, funding sources, and
study aim), (ii) human participant characteristics (age,
height, sex, body mass, body mass index, body fat %, type
and duration of condition, activity and exercise levels, and
dietary information), (iii) animal characteristics (age, body
mass, source, species, strain, sex, developmental stage,
genetic modification status, genotype, type and duration
of condition, method used to induce disease, and housing
conditions), (iv) intervention characteristics (name, type of
control used, dosage, frequency, duration, route of admin-
istration), and (v) outcome characteristics for glycaemic
control and insulin resistance (type of measure, sample
sizes, baseline, interim, and post-intervention measures of
central tendency and dispersion, adherence to the
Table 1 Overview of PICOS eligibility criteria
Participants Humans with a diagnosis of type 1 diabetes, type 2 diabetes, prediabetes, gestational diabetes, impaired fasting glucose, or impaired
glucose tolerance (according to WHO guidelines [21, 22]), or humans with overweight/obesity (BMI ≥ 25 kg.m2) where the relevant
outcomes were collected and reported.
Animal studies using a diabetes-related disease model (see human criteria above), or overweight/obese animals where the relevant
outcomes were collected and reported.
There will be no restriction on age or comorbidities and no restrictions on the methods used to induce disease in animal studies.
Intervention Supplementation with carnosine or β-alanine. We will exclude studies that use a multi-ingredient supplement intervention.
Human studies will include oral administration only, whereas in animal studies we will also consider administration by other means
(e.g. intraperitoneal or intravenous injection).
Comparator Comparisons for human studies will be between placebo and the experimental intervention.
Comparisons for animal studies will be between placebo or control (no intervention) and the experimental intervention.
Studies without a control or placebo group will be excluded.
Outcomes Outcomes relating to glycaemic control and insulin resistance. Primary outcomes include changes in (i) fasting glucose, (ii) glycated
haemoglobin, and (iii) 2-h glucose following a glucose tolerance test. Additional outcomes include changes in fasting insulin, glucose
tolerance test parameters, and homeostatic model assessment parameters (see supporting information for a full list).
Study
designs
Studies will be limited to non-randomised and RCTs, including cluster RCTs. We will exclude cohort studies, cross-sectional studies, case
series, case reports, commentary, and review articles.
BMI body mass index, RCTs randomised controlled trials, WHO World Health Organization
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intervention, dropouts, number and nature of side effects,
and assessment of blinding to the intervention). We will
also extract information relevant to measures of risk of
bias and quality assessment. Where necessary, measures
of central tendency and dispersion will be extracted from
figures in the articles using WebPlotDigitizer version 3.10
(https://apps.automeris.io/wpd/). If parameters cannot be
adequately calculated, we will contact study authors for
additional data (maximum of three e-mail attempts).
Outcomes and prioritisation
The three primary outcomes will be changes in fasting
glucose (FG) (includes plasma, serum, and blood glucose
values), glycated haemoglobin (HbA1c), and 2-h glucose
following a glucose tolerance test (GTT). These out-
comes represent the three clinical markers used in the
diagnosis of type 1 diabetes, type 2 diabetes, prediabetes,
and gestational diabetes [21, 22]. Additional outcomes
include changes in other markers of glycaemic control
and insulin resistance (for a full list see supporting
information).
Risk of bias in individual studies
Risk of bias in individual human studies will be assessed
using the Cochrane risk of bias 2.0 tool (RoB 2.0) for
assessing risk of bias in randomised trials [25] and in in-
dividual animal studies using the Systematic Review
Centre for Laboratory Animal Experimentation (SYRC
LE) tool [26]. Reviewers will assess each study item as ei-
ther “high risk”, “low risk”, “some concerns” (RoB 2.0),
or “unclear risk” (SYRCLE) of bias. All disagreements
and referrals will be recorded.
Data synthesis
Data will be presented in summary tables to describe the
study population and intervention. We will conduct meta-
analyses using appropriate models to account and explore
for variation within and between studies. All meta-
analyses will be conducted within a Bayesian framework,
providing a flexible modelling approach to account for un-
certainty in model parameters and underlying structures
within the data. Additionally, Bayesian models will enable
results to be interpreted more intuitively through report-
ing subjective probabilities rather than null hypothesis
tests or frequentist confidence intervals [27]. Each of the
primary and additional outcomes will be extracted and
analysed as continuous measures. For primary outcomes,
the effect of each study will be estimated by calculating
the pre-post raw scale mean difference between interven-
tion and control. Modelling outcomes on the same abso-
lute scale as the original measurement will provide more
interpretable findings. Effect size estimates for additional
outcomes will be standardised using reported standard de-
viations to account for differences in measurement scales.
Standard threshold values of 0.2, 0.5, and 0.8 will be used
to describe effect size estimates as small, medium, and
large, respectively [28]. Values between 0 and 0.2 will be
described as trivial. Three-level Bayesian hierarchical
models will be used to pool effect sizes and model average
effect, variance within studies, variance between studies,
and covariance of multiple outcomes reported in the same
study (e.g. single outcome variable reported at intermedi-
ate testing points). Informative priors will be used to esti-
mate within-study variances and account for unknown
correlations between pre and post values of the different
outcomes. Non-informative priors will be used for all
other model parameters. Inconsistency in models will be
described by comparing variances across the three levels.
Inferences from all analyses will be performed on poster-
ior samples generated by Hamiltonian Markov chain
Monte Carlo and through the use of credible intervals and
calculated probabilities. Analyses will be performed using
the R wrapper package brms interfaced with Stan to per-
form sampling [29].
Sensitivity analyses will be performed to examine the
robustness of the outcomes by excluding studies at high
risk of bias. Animal and human studies will be aggre-
gated if sufficient data are available and meta-regressions
indicate no substantive difference in the median pooled
effect size estimate. Meta-regressions where possible will
be used to explore the effect of type of supplementation
(carnosine or β-alanine), duration of supplementation,
and the disease type. Meta-regressions using categorical
variables will be performed where there are at least four
data points for each factor level.
Meta-biases
Outcome reporting bias
Where possible, we will screen clinical trial registers to
compare outcomes reported in the protocol with each
published report. Where there is no preregistration or
protocol, we will compare the outcomes reported in the
methods and results section of each published report.
Small study bias (includes publication and study quality bias)
We will visually inspect funnel plots and assess using a
multi-level extension of Egger’s regression test [30].
Confidence in cumulative evidence
The quality of evidence for each outcome will be
assessed using the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach
[31], which assesses quality across five domains: risk of
bias, inconsistency (heterogeneity), indirectness, impreci-
sion, and publication bias. Quality will be graded as
“high”, “moderate”, “low”, or “very low” (Table 2). Out-
comes from randomised controlled trials begin as “high”
quality evidence and can be downgraded for issues in
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each domain. Outcomes can also be upgraded when
there is evidence of a large magnitude of effect, presence
of a dose-response gradient, and all plausible con-
founders of other biases increase the confidence in the
estimated effect [33]. The approach and procedures will
be the same as for study selection and data extraction.
Discussion
This systematic review and meta-analysis will synthesise
evidence to determine the effect of carnosine or β-alanine
supplementation on markers of glycaemic control and in-
sulin resistance. By including all available human and
animal data, we will provide the most comprehensive
overview on the topic to date. Further, the proposed
meta-analysis will explore the factors associated with posi-
tive outcomes and highlight promising avenues of future
research. The results will have implications for those
working in prediabetes, diabetes, and metabolic health in
general and may lead to the development of new treat-
ment approaches.
Dissemination
The study results will be presented at a professional con-
ference and published in a peer-reviewed journal.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s13643-020-01539-8.
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